Strong Independent Association of TILs with OS for Patients with ERBB2-positive Early Breast Cancer By Ogkologos - February 26, 2025 620 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from updated analysis of the ShortHER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR The new home for your research tools April 11, 2022 Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... December 6, 2024 Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health December 23, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Eribulin Cancer in My Community: Working to Expand Access to Clinical Trials... How to Strengthen Your Immune System: Part 2 FDA Approves First Immunotherapy Treatment For Breast Cancer
